First National Trust Co Has $8.22 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

First National Trust Co lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 13,288 shares of the medical research company’s stock after selling 99 shares during the quarter. First National Trust Co’s holdings in Thermo Fisher Scientific were worth $8,220,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Meeder Asset Management Inc. lifted its position in shares of Thermo Fisher Scientific by 13.7% during the 1st quarter. Meeder Asset Management Inc. now owns 573 shares of the medical research company’s stock worth $333,000 after purchasing an additional 69 shares during the last quarter. Verus Capital Partners LLC bought a new stake in Thermo Fisher Scientific in the first quarter valued at about $232,000. Headlands Technologies LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $32,000. Entropy Technologies LP increased its holdings in Thermo Fisher Scientific by 45.4% during the 1st quarter. Entropy Technologies LP now owns 7,099 shares of the medical research company’s stock valued at $4,126,000 after purchasing an additional 2,218 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Thermo Fisher Scientific by 0.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 183,156 shares of the medical research company’s stock worth $106,452,000 after acquiring an additional 1,565 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,150 shares of company stock worth $15,676,125 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $546.92 on Tuesday. Thermo Fisher Scientific Inc. has a twelve month low of $439.11 and a twelve month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $209.20 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 3.65 and a beta of 0.79. The stock has a fifty day simple moving average of $593.95 and a 200 day simple moving average of $583.73.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same period in the prior year, the firm earned $5.69 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TMO. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank increased their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Bank of America raised their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Sanford C. Bernstein cut their target price on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday, October 24th. Finally, Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.